A Two-part, Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.

Trial Profile

A Two-part, Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 20 Oct 2012 Planned number of patients changed from 488 to 575.
    • 02 Mar 2011 Results have been reported in a GW Pharmaceuticals media release.
    • 14 Oct 2010 According to an Almirall media release, results from 3 pivotal clinical studies of tetrahydrocannabinol/cannabidiol (Sativex) were presented in a satellite symposium at the 26th annual congress of the ECTRIMS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top